Musso G, Gambino R, Cassader M
However, following Wegovy's 2024 FDA approval for cardiovascular risk reduction, CMS issued guidance allowing Medicare Part D plans to cover Wegovy when prescribed for its cardiovascular indication in eligible patients
GLP-1 treatment for diabetes and obesity Semaglutide, a GLP-1 receptor agonist, is the active ingredient in Ozempic for diabetes and in Wegovy for obesity
They jump straight to the standard 2.5 mg weekly dose, experience a wave of nausea that lasts for days, and either white-knuckle through it or quit entirely
Brittany was great, didn't try to push anything on me and knew exactly what I wanted
The newer drugs represent a genuine breakthrough, offering results that approach bariatric surgery outcomes without requiring invasive procedures